<DOC>
	<DOCNO>NCT00471328</DOCNO>
	<brief_summary>The study evaluate safety efficacy nilotinib versus current treatment adult gastrointestinal stromal tumor ( GIST ) either progress intolerant first second line treatment .</brief_summary>
	<brief_title>Efficacy Safety Nilotinib ( AMN107 ) Compared With Current Treatment Options Patients With GIST Who Have Failed Both Imatinib Sunitinib</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Inclusion criterion ( Core Phase ) : Age ≥18 year Radiological confirmation disease progression imatinib sunitinib therapy OR intolerance imatinib and/or sunitinib At least one measurable site disease CT/MRI scan Physically fit even able work Normal organ , electrolyte , bone marrow function Inclusion criterion ( Extension Phase ) : Patients whose tumor progress control arm cross nilotinib arm . The study stop due meeting primary efficacy endpoint PFS interim analysis . Patients still treat close Core study control arm nilotinib arm ( whose tumor progress time end Core study ) . Patients must document , confirm stable , partial complete response define RECIST criterion time entry Extension study exception patient progress control arm . Exclusion criterion ( Core Phase ) : Previous treatment nilotinib drug class target therapy Treatment cytotoxic and/or investigational cytotoxic drug ≤ 4 week prior study entry Impaired cardiac function Use coumarin derivative ( i.e . warfarin , acenocoumarol , phenprocoumon ) Women pregnant lactate Exclusion criterion ( Extension Phase ) : Use anticancer treatment investigational drug ( exception study drug ) Patients history noncompliance study drug treatment Core study protocol . Other protocoldefined inclusion/exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>GIST</keyword>
	<keyword>adult</keyword>
	<keyword>imatinib resistant</keyword>
	<keyword>sunitinib resistant</keyword>
	<keyword>AMN107</keyword>
	<keyword>nilotinib</keyword>
	<keyword>treatment</keyword>
	<keyword>Gastrointestinal stromal tumor ( GIST )</keyword>
</DOC>